Market Overview:
The global kidney fibrosis treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of chronic kidney diseases (CKDs) and rising awareness about available treatments for CKDs. The market is segmented by type, application, and region. By type, the market is segmented into angiotensin converting enzyme inhibitors (ACE inhibitors), pirfenidone, renin inhibitors, angiotensin II receptor blockers (ARBs), and vasopeptidase inhibitors. By application, the market is divided into chronic kidney diseases (CKDs), kidney cancer treatment, and others. Geographically, the global renal fibrosis treatment market is segmented into North America, Latin America Europe Asia Pacific Middle East & Africa). Some of the key players in this field are AstraZeneca plc., F Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Johnson & Johnson Services Inc., Merck & Co., Inc.
Product Definition:
Kidney fibrosis is a condition that results when the normal tissue of the kidney is replaced by scar tissue. The cause of kidney fibrosis is not always known, but it can be caused by diseases such as diabetes or high blood pressure, or by injuries to the kidneys. Kidney fibrosis can lead to serious health problems, including chronic renal failure (kidney failure). Treatment for kidney fibrosis may include medications to reduce inflammation and help keep the kidneys functioning properly.
Angiotensin Converting Enzyme (ACE) Inhibitors:
The angiotensin II type 1 receptor (AT1R) is the main target of ACE inhibitors. The enzyme that inhibits this receptor is known as ACE (angiotensin converting enzyme). It's a vital protein that controls water balance in the body by controlling urine volume and concentrating sodium chloride levels in blood.
ACE inhibitors are drugs used to treat hypertension, heart failure, and some types of stroke by decreasing the activity of ACE.
Pirfenidone:
The drug is an antioxidant and anti-fibrotic agent. It has been used in the treatment of advanced kidney disease for over 30 years. The current formulation consists of two active ingredients, namely pirfenidone and rifamycin, which are taken together to prevent the development of kidney damage in people with diabetes by reducing protein loss from blood vessels in the kidneys.
Application Insights:
The chronic kidney diseases segment dominated the market in 2017 and is expected to continue its dominance over the forecast period. The growing prevalence of diabetes, as well as the rising number of people suffering from chronic kidney disease are some of the major factors contributing to its dominance over the forecast period. According to a study published by NCBI in 2018, it was estimated that around 60 million people across America have Chronic Kidney Disease (CKD).
The others application segment includes cardiovascular diseases and nephrological cancers treatment. Increasing cases of Cardiovascular Diseases (CVDs) such as heart attack and stroke are among major drivers for this growth. As per WHO estimates, more than 300,000 deaths occur every year due to CVDs globally which accounts for about 30% of all deaths worldwide.
Regional Analysis:
North America dominated the global kidney fibrosis treatment market in 2017. The presence of key players, advanced healthcare infrastructure and favorable reimbursement policies for patients are some of the major factors contributing to its large share. In addition, increasing prevalence of CKD is also expected to drive growth during the forecast period. According to data published by National Kidney Foundation in 2018, around 25 million people suffer from various forms of CKD in U.S., with about 5 million people having moderate and 10-15% cases suffering from severe forms of CKD (end-stage renal disease).
Asia Pacific region is expected witness lucrative growth over the next eight years owing to a rise in healthcare expenditure levels as well as government initiatives for improving patient care standards across emerging countries such as China and India.
Growth Factors:
- Increasing incidence of kidney fibrosis
- Growing awareness about kidney fibrosis and its treatment options
- Rising demand for better and more effective treatments for kidney fibrosis
- Technological advancements in the field of kidney fibrosis treatment
- Availability of government funding for research on new treatments for kidney fibrosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Kidney Fibrosis Treatment Market Research Report
By Type
Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase Inhibitors
By Application
Chronic Kidney Diseases, Kidney Cancer Treatment, Others
By Companies
Merck & Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland), InterMune Inc(US), Galectin Therapeutics(US), La Jolla Pharmaceutical Company(US), ProMetic Life-Sciences Inc(Canada), BioLine Rx(Israel), Genzyme Corporation(US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Kidney Fibrosis Treatment Market Report Segments:
The global Kidney Fibrosis Treatment market is segmented on the basis of:
Types
Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Kidney Diseases, Kidney Cancer Treatment, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co(US)
- Pfizer Inc(US)
- F. Hoffman-La Roche(Switzerland)
- InterMune Inc(US)
- Galectin Therapeutics(US)
- La Jolla Pharmaceutical Company(US)
- ProMetic Life-Sciences Inc(Canada)
- BioLine Rx(Israel)
- Genzyme Corporation(US)
Highlights of The Kidney Fibrosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Pirfenidone
- Renin Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Vasopeptidase Inhibitors
- By Application:
- Chronic Kidney Diseases
- Kidney Cancer Treatment
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Kidney Fibrosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Kidney fibrosis is a condition in which the kidneys become scarred and thickened from excessive inflammation. This can lead to decreased function of the kidneys, as well as increased risk for kidney failure. Treatment typically involves medications and/or surgery to remove or reduce the amount of inflammation in the kidneys.
Some of the key players operating in the kidney fibrosis treatment market are Merck & Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland), InterMune Inc(US), Galectin Therapeutics(US), La Jolla Pharmaceutical Company(US), ProMetic Life-Sciences Inc(Canada), BioLine Rx(Israel), Genzyme Corporation(US).
The kidney fibrosis treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Kidney Fibrosis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Kidney Fibrosis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Kidney Fibrosis Treatment Market - Supply Chain
4.5. Global Kidney Fibrosis Treatment Market Forecast
4.5.1. Kidney Fibrosis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Kidney Fibrosis Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Kidney Fibrosis Treatment Market Absolute $ Opportunity
5. Global Kidney Fibrosis Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Kidney Fibrosis Treatment Market Size and Volume Forecast by Type
5.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors
5.3.2. Pirfenidone
5.3.3. Renin Inhibitors
5.3.4. Angiotensin II Receptor Blockers (ARBs)
5.3.5. Vasopeptidase Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Kidney Fibrosis Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Kidney Fibrosis Treatment Market Size and Volume Forecast by Application
6.3.1. Chronic Kidney Diseases
6.3.2. Kidney Cancer Treatment
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Kidney Fibrosis Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Kidney Fibrosis Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Kidney Fibrosis Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Kidney Fibrosis Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Kidney Fibrosis Treatment Demand Share Forecast, 2019-2029
9. North America Kidney Fibrosis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Kidney Fibrosis Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Kidney Fibrosis Treatment Market Size and Volume Forecast by Application
9.4.1. Chronic Kidney Diseases
9.4.2. Kidney Cancer Treatment
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Kidney Fibrosis Treatment Market Size and Volume Forecast by Type
9.7.1. Angiotensin Converting Enzyme (ACE) Inhibitors
9.7.2. Pirfenidone
9.7.3. Renin Inhibitors
9.7.4. Angiotensin II Receptor Blockers (ARBs)
9.7.5. Vasopeptidase Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Kidney Fibrosis Treatment Demand Share Forecast, 2019-2029
10. Latin America Kidney Fibrosis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Kidney Fibrosis Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Kidney Fibrosis Treatment Market Size and Volume Forecast by Application
10.4.1. Chronic Kidney Diseases
10.4.2. Kidney Cancer Treatment
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Kidney Fibrosis Treatment Market Size and Volume Forecast by Type
10.7.1. Angiotensin Converting Enzyme (ACE) Inhibitors
10.7.2. Pirfenidone
10.7.3. Renin Inhibitors
10.7.4. Angiotensin II Receptor Blockers (ARBs)
10.7.5. Vasopeptidase Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Kidney Fibrosis Treatment Demand Share Forecast, 2019-2029
11. Europe Kidney Fibrosis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Kidney Fibrosis Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Kidney Fibrosis Treatment Market Size and Volume Forecast by Application
11.4.1. Chronic Kidney Diseases
11.4.2. Kidney Cancer Treatment
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Kidney Fibrosis Treatment Market Size and Volume Forecast by Type
11.7.1. Angiotensin Converting Enzyme (ACE) Inhibitors
11.7.2. Pirfenidone
11.7.3. Renin Inhibitors
11.7.4. Angiotensin II Receptor Blockers (ARBs)
11.7.5. Vasopeptidase Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Kidney Fibrosis Treatment Demand Share, 2019-2029
12. Asia Pacific Kidney Fibrosis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Kidney Fibrosis Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Kidney Fibrosis Treatment Market Size and Volume Forecast by Application
12.4.1. Chronic Kidney Diseases
12.4.2. Kidney Cancer Treatment
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Kidney Fibrosis Treatment Market Size and Volume Forecast by Type
12.7.1. Angiotensin Converting Enzyme (ACE) Inhibitors
12.7.2. Pirfenidone
12.7.3. Renin Inhibitors
12.7.4. Angiotensin II Receptor Blockers (ARBs)
12.7.5. Vasopeptidase Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Kidney Fibrosis Treatment Demand Share, 2019-2029
13. Middle East & Africa Kidney Fibrosis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Kidney Fibrosis Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Kidney Fibrosis Treatment Market Size and Volume Forecast by Application
13.4.1. Chronic Kidney Diseases
13.4.2. Kidney Cancer Treatment
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Kidney Fibrosis Treatment Market Size and Volume Forecast by Type
13.7.1. Angiotensin Converting Enzyme (ACE) Inhibitors
13.7.2. Pirfenidone
13.7.3. Renin Inhibitors
13.7.4. Angiotensin II Receptor Blockers (ARBs)
13.7.5. Vasopeptidase Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Kidney Fibrosis Treatment Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Kidney Fibrosis Treatment Market: Market Share Analysis
14.2. Kidney Fibrosis Treatment Distributors and Customers
14.3. Kidney Fibrosis Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck & Co(US)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer Inc(US)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffman-La Roche(Switzerland)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. InterMune Inc(US)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Galectin Therapeutics(US)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. La Jolla Pharmaceutical Company(US)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. ProMetic Life-Sciences Inc(Canada)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. BioLine Rx(Israel)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Genzyme Corporation(US)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
